Recombinant Mouse Claudin-18.2 (Cldn18.2)-VLPs (Active)

This Mouse Claudin-18 (Cldn18) recombinant protein was produced in mammalian cell, where the gene sequence encoding mouse Cldn18 (1-264aa) was expressed with the N-terminal 6xHis tag. The activity was validated. In addition, this mouse Cldn18 recombinant protein was developed through the Virus-Like Particles (VLPs) Platform. It is a four-pass transmembrane protein.

CLDN18 belongs to one of the tight junction protein family, and its isoform CLDN18.2 is highly expressed in a variety of tumor tissues, such as gastric cancer (60%-80%), pancreatic cancer (50%), esophageal cancer (30%-50%), and lung cancer (40%~60%), etc., but almost no expression in normal tissues, so it has excellent therapeutic potential. Even in the metastatic lesions of gastric cancer, CLDN18.2 has a high expression level, which makes CLDN18.2 a potential target for targeted therapy and immunotherapy.
CLDN18 was initially identified as a target gene of the transcription factor t/ebp/nkx2.1, consistent with its homology to other Claudin family members, and CLDN18 was later shown to localize at cellular tight junctions in mice and humans. The full-length murine CLDN18 protein is 264 amino acids, and its homology with human CLDN18.2 protein is as high as 90%. Its structure is similar to that of human. Both of them have four transmembrane domains: the intracellular NH2 terminus & COOH-terminus and two extracellular loops ECL1 & ECL2.